PATENT CLAIM ANALYSIS

Application Number: 16414350
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "499000"]

Abstract:
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Claim (Index 2):
The pharmaceutical nasal dosage form of  claim 1 , wherein said pharmaceutical nasal dosage form requires less than about 15 minutes to administer an effective dose of dihydroergotamine.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.69565
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12069667', '12839190', '15471334', '12548292', '14921860']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7975535829410814
- 35 USC 102 Novelty (BERT): 0.5119620887515692
- Combined Prediction Score: 0.7689944335221303
- Mean Citation Score: 300.153426
- Max Citation Score: 311.41263
- Similarity Product: 247.5603684476924

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test